Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06297785
Other study ID # 2022-03997-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 17, 2022
Est. completion date April 2027

Study information

Verified date May 2024
Source Sahlgrenska University Hospital, Sweden
Contact Jenny Lövdahl, Reg. Nurse, hypnotherapist
Phone 0313428107
Email magtarmlab.su@vgregion.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Adult IBS patients with symptoms refractory to standard medical treatment will receive online nurse-administered, gut-directed hypnotherapy in groups. The primary outcome measure was change in gastro-intestinal symptom severity.


Description:

IBS patients with symptoms refractory to standard treatment and who were referred to a specialist unit for hypnotherapy, will be included in the study consecutively. The patients will receive gut-directed hypnotherapy given by a nurse trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. Effects of treatment will be measured by validated questionnaires at baseline and at various time points during the treatment period, as well as after the completion of the treatment at follow-up 6 months, 1 and 2 years after treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date April 2027
Est. primary completion date April 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - IBS diagnosis Exclusion Criteria: - Organic GI disease

Study Design


Intervention

Behavioral:
Gut-directed hypnotherapy
Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.

Locations

Country Name City State
Sweden Mag-Tarmlab, Sahlgrenska University Hospital Gothenburg
Sweden Sahlgrenska University Hospital Gothenburg

Sponsors (1)

Lead Sponsor Collaborator
Sahlgrenska University Hospital, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in gastrointestinal symptom severity measured by the IBS Severity Scoring System questionnaire (IBS-SSS) The score is calculated from 5 items: pain severity, pain frequency, abdominal bloating severity, bowel habit dissatisfaction and daily life interference. The score ranges from 0-500. A higher the score signifies more severe symptoms. A symptom score reduction of 50 points or more after treatment compared to the baseline score is considered a response to treatment. Baseline (week 0), during treatment (week 6), at treatment completion (week 12), follow-up (6 months, 1 and 2 years after treatment initiation)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05118243 - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) N/A
Completed NCT05197413 - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms N/A
Completed NCT04905524 - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP) N/A
Recruiting NCT05874830 - The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome N/A
Active, not recruiting NCT04723056 - Zemedy Application for Irritable Bowel Syndrome N/A
Completed NCT05565612 - Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome N/A
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Completed NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Recruiting NCT06215222 - Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
Completed NCT05016596 - Postprandial Lipids in IBS and Nutritional Treatment N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Completed NCT06426745 - Split-dose Versus Single-dose Bowel Preparation for Colonoscopy N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Recruiting NCT05990764 - Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS) N/A
Completed NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A
Completed NCT04898257 - Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients N/A